Digital
October 22nd - 23rd, 2020

3rd Annual MarketsandMarkets Real-World Data, Life Sciences Analytics and Market Access Virtual Conference ( Time Zone - EASTERN STANDARD TIME (EST)

MarketsandMarkets is proud to announce the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference to be held on October 22nd -23rd, 2020.

While the 2nd annual Congress had discussions on accelerating the adoption of Real-world Evidence within the industry while understanding the capabilities of newer technologies for evidence generation, the 3rd Annual will focus on how the insights derived from real world data, as well as acknowledgment of the effect the insights can have on improving decision making and patient consideration both internally and by regulators, doctors, and payers.

Our aim for the 3rd Annual Real-World Data, Life Sciences Analytics and Market Access – Virtual Conference is to unite all stakeholders in a virtual room during these remarkable times to see how to use conventional informational indexes and layer that in with innovative analytical techniques and new working models.

The virtual conference will also hold discussion on the impact due to COVID-19 in RWD space- Identifying and overcoming those challenges efficiently

WHAT TO EXPECT
Key Highlights
  • Progression on uses of Real-World Data across the ecosystem
  • Global regulatory perspective on Real-World Evidence Guidance- FDA & EMA
  • Applications of Artificial Intelligence & Blockchain for Real-World Data Analysis
  • Market Access and Pricing
  • COVID-19 impact- Identifying and overcoming challenges in Real-World Evidence space
Who Should Attend?

From pharmaceutical and Biopharmaceutical companies-

Chief executives, VP’s, Directors, Global heads, Heads, Leaders, Senior Managers, Researcher, Analysts, Investigators, Scientists, Bio-Statisticians, Epidemiologist, within the following departments

  • Real-World Evidence
  • Health Economics & Outcomes Research
  • Patient Access
  • Value Access
  • Clinical Operations
  • Clinical Development
  • Center for Observational and Real-World Evidence  

 

Why Attend?
  • Understand the impact of innovative real-world evidence partnerships for better data
  • To explore the capabilities of using Artificial Intelligence & Machine Learning for better Data Analysis
  • Learn about global regulatory perspective on Real-World Evidence Guidance
  • Learn about best practices for the commercial structure of drugs, from development to market access strategy
  • Opportunity to network and exchange scientific knowledge with expert speakers from leading manufacturers, global regulators, and solution providers
CONFERENCE AGENDA

Registration

08:30 - 09:00

Welcome note from MarketsandMarkets

09:00 - 09:05
PROGRESSION ON USES OF REAL-WORLD DATA ACROSS THE ECOSYSTEM

Opening Remarks from the Chairman

09:05 - 09:10 Angela Ibald-Mulli , Head, Medical Evidence Generation Primary Care , Sanofi

Keynote Presentation: Building and scaling organizational RWE capabilities to maximize return

09:10 - 09:40 Charles Makin , Global Head, Real World Evidence Strategy , Biogen

Multiple sclerosis outcomes database

09:40 - 10:10 Guru Rao KS, Senior Vice President, Molecular Connections Private Limited

Real-World Evidence in Drug Development: The FDA Experience

10:10 - 10:40 Nneka Onwudiwe, Former PRO/PE Regulatory Review Officer, FOOD AND DRUG ADMINISTRATION

Using Real World Clinical NGS Data for Precision Oncology

10:40 - 11:15 Sheryl Krevsky Elkin , Chief Scientific Officer , QIAGEN Digital Insights

One-to-One Networking Meetings | Networking break

11:15 - 11:35
ARTIFICIAL INTELLIGENCE, BLOCKCHAIN AND BIG DATA: GAMECHANGER IN REAL-WORLD EVIDENCE GENERATION

Advanced real-world evidence as a competitive advantage

11:35 - 12:05 Dan Riskin , Founder and CEO, Verantos

Considerations and challenges around AI enabled clinical decision support

12:05 - 12:35 Angela Ibald-Mulli , Head, Medical Evidence Generation Primary Care , Sanofi

BigData & Artificial Intelligence: separating facts from fiction

12:35 - 13:05 Ignacio Hernandez Medrano, Founder, Savana Medica

Challenges and opportunities on generating “regulatory grade” Real World Evidence

13:05 - 13:35 David Miller, Executive Director, Head of RWE- Patient Safety, Sarepta Therapeutics, USA

Closing remarks from the Chairperson

13:35 - 13:40

One-to-One Networking Meetings | Networking break

13:40 - 14:30
IMPLICATIONS OF MARKET ACCESS AND PATIENT ACCESS TO MEASURE IMPACT

Opening Remarks from the Chairman

09:05 - 09:10 Tao Fan , Senior Director, US HEOR US Medical Office , Takeda Pharmaceuticals

Market Access & Pricing / What do you need to consider for a success drug launch?

09:10 - 09:40 Raymond Frost, Vice President, Market Access & Health Policy, Melinta

Innovative Payment Models: Practical Learnings from the US Launch of the First Gene Therapy for a Genetic Disease

09:40 - 10:10 Jay Newman, Head of US Commercial, Spark Therapeutics

Integrating Real-World Datasets to Understand Socio-Economic Disparities in Access to Healthcare

10:10 - 10:40 Tom Haskell, Global Head of Data Analytics , Kantar Health

Generating Real World Evidence in Medical Affairs: Challenges and New Opportunities

10:40 - 11:15 Andrei Pikalov, Vice President, Head of Global Medical Affairs, Sunovion Pharmaceuticals

One-to-One Networking Meetings | Networking break

11:15 - 11:35
GLOBAL REGULATORY PERSPECTIVE ON REAL-WORLD EVIDENCE GUIDANCE

RWE for regulatory and HTA decision-making: latest precedent and what’s ahead

11:35 - 11:50 Ashley Jaksa, VP of Science , Aetion

Panel discussion- Assessing the upcoming changes in the regulatory landscape in terms of Real-World Data- FDA, EMA, PMDA & industry perspective

11:50 - 12:35

Comprehensive real-world evidence generation strategy to support reimbursement and market access

12:35 - 13:05 Eliza Kruger, Associate Director, Global HEOR, Ultragenyx Pharmaceuticals

Closing remarks from the Chairperson

13:05 - 13:10

One-to-One Networking Meetings | Networking break

13:10 - 14:30

Registration

08:30 - 08:55

Welcome note from MarketsandMarkets

08:55 - 09:00

Opening Remarks from the Chairman

09:00 - 09:05 Eliza Kruger, Associate Director, Global HEOR, Ultragenyx Pharmaceuticals
NEW FORMS OF REAL-WORLD DATA

What are Registries for Rare Diseases?

09:05 - 09:35 Rafael Ioschpe, Associate Director, RWE Strategic Operations Lead, Rare Disease, , Sanofi Genzyme

Impact of COVID-19 on the generation and use of real-world data and evidence

09:35 - 10:05 Nirosha Lederer , Managing Associate, Real World Evidence, Duke Margolis Center for Health Policy, Duke University

Best Practices in Long-Term Safety Follow-Up Studies – Using technology to ensure safety and lighten site and patient burden

10:05 - 10:35 Noolie Gregory, Executive Director, Client Engagement Solutions, Real World Late Phase, Syneos Health

Generating Real-World Evidence For Stakeholders Including Physicians, Patients, and Payers

10:35 - 11:00 Shaum Kabadi, Director of Global Real-World Evidence in Oncology, AstraZeneca

Causal Inference Methods for Real World Evidence: a Case Study of a Target Trial Emulation

11:00 - 11:30 Xabier Garcia de Albeniz Martinez , Director, Epidemiology , RTI Health Solutions

One-to-One Networking Meetings | Networking break

11:30 - 11:50
BREAKTHROUGH TO EXCELLENT DATA EVALUATION

Real-World Data Hubs - technology platforms to enable clinical outcome & RWE collaborations between hospitals and Life Sciences Industry

11:50 - 12:20 Georges De Feu, Founder & CEO, Lynxcare

Real World Data in a pandemic: Making sense of EHR data for COVID-19

12:20 - 12:50

Closing remarks from the Chairman

12:50 - 12:55
CONFERENCE SPEAKERS
Speakers
Charles Makin

Charles Makin

Global Head, Real World Evidence Strategy
Biogen

Charles Makin

Global Head, Real World Evidence Strategy
Biogen
Nneka Onwudiwe

Nneka Onwudiwe

Former PRO/PE Regulatory Review Officer
FOOD AND DRUG ADMINISTRATION

Nneka Onwudiwe

Former PRO/PE Regulatory Review Officer
FOOD AND DRUG ADMINISTRATION
Vic Spain

Vic Spain

Senior Real World Data Scientist
Genentech

Vic Spain

Senior Real World Data Scientist
Genentech
David Miller

David Miller

Executive Director, Head of RWE- Patient Safety
Sarepta Therapeutics, USA

David Miller

Executive Director, Head of RWE- Patient Safety
Sarepta Therapeutics, USA
Nirosha Lederer

Nirosha Lederer

Managing Associate, Real World Evidence
Duke Margolis Center for Health Policy, Duke University

Nirosha Lederer

Managing Associate, Real World Evidence
Duke Margolis Center for Health Policy, Duke University
Alexander Cole

Alexander Cole

Executive Director, Global Head Epidemiology
Alexion Pharmaceuticals

Alexander Cole

Executive Director, Global Head Epidemiology
Alexion Pharmaceuticals
Raymond Frost

Raymond Frost

Vice President, Market Access & Health Policy
Melinta

Raymond Frost

Vice President, Market Access & Health Policy
Melinta
Eliza Kruger

Eliza Kruger

Associate Director, Global HEOR
Ultragenyx Pharmaceuticals

Eliza Kruger

Associate Director, Global HEOR
Ultragenyx Pharmaceuticals
SPONSORS
Sponsors & Exhibitors
example-image

Adelphi Real World

example-image

Picnic Health

example-image

OPEN Health

example-image

Premier Inc.

Speaking Partner
example-image

QIAGEN

example-image

Verantos

example-image

Syneos Health

example-image

Molecular Connections

example-image

Kantar

example-image

Savana

example-image

Aetion

example-image

RTI Health Solutions

example-image

LynxCare

PAST EVENT GALLERY
  • Networking-Room
  • Networking-Event
  • Networking-Exhibition-Audience
  • Networking-Exhibition
  • Discussion-Conference-Audience
  • Conference-Speaker
  • Conference-Audience-Discussion
  • Conference-Room-Audience
  • Conference-Room
  • Conference-Audience
  • High Potent Medicines Conference - Networking area
  • High Potent Medicines Conference - Exhibition Area - Booths